The first set of presentation videos from Undoing Aging are now available online, via the conference YouTube channel. The conference was held earlier this year in Berlin, jointly hosted by the SENS Research Foundation and Forever Healthy Foundation. The former should need no introduction here, while the latter was founded by philanthropist and investor Michael Greve, a strong supporter of the SENS rejuvenation research programs. By all accounts the conference was a rousing success, adding to a series of past events that have brought together research and industry interests focused on the development of rejuvenation therapies after the SENS model of damage repair. Undoing Aging will return again next year:
Due to the incredible success of the 2018 Undoing Aging Conference in Berlin, Germany, SENS Research Foundation and Michael Greve's Forever Healthy Foundation are pleased to announce that Undoing Aging will return in 2019. This will be an annual conference series, co-sponsored by SRF and FHF to promote awareness of age-related disease and the ongoing scientific breakthroughs in rejuvenation biotechnology. Undoing Aging 2019 will once again focus on bringing together scientists from around the globe in their respective fields who are leading the charge in combating age-related disease. It is through the collaborative efforts of these scientists, investors, policy makers, and media that we will continue to expand the rejuvenation biotechnology industry and reimagine aging.
Kelsey Moody is CEO and Founder at Ichor Therapeutics, a pre-clinical biotechnology company with a focus on drug development for age-associated disease. The two SENS categories that have, arguably, seen the greatest contribution from research funded by the SENS Research Foundation are those relating to damage within cells: mitochondrial mutations and "garbage". Our in-house team has made immense progress recently in rendering mitochondrial mutations harmless by installing "backup copies" in the nuclear genome, while Ichor Therapeutics has taken on one strand of the garbage removal work. Kelsey Moody will describe the state of play in relation to elimination of one of the best-characterised types of intracellular garbage, part of the lipofuscin that drives development of macular degeneration.
Brian Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of delaying, detecting, preventing and treating human aging and associated diseases. From 2010 to 2016 he was the President and CEO of the Buck Institute for Research on Aging, and is now Director of the Center for Healthy Ageing at the Yong Loo Lin School of Medicine at National University Singapore. He here talks about the arrival of Singapore in the aging research community, outlining some of the lines of research underway in that country.